Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors (original) (raw)

• Steinberg, D. & Gotto, A. M. Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. JAMA 282, 2043–2050 (1999). An excellent concise historical overview.
  CAS PubMed Google Scholar
• Kannel, W. B. Clinical misconceptions dispelled by epidemiological research. Circulation 92, 3350–3360 (1995).
  CAS PubMed Google Scholar
• Keys, A. et al. The seven countries study: 2,289 deaths in 15 years. Prev. Med. 13, 141–154 (1984).
  CAS PubMed Google Scholar
• Peto, R., Yusuf, S. & Collins, R. Cholesterol-lowering trials in their epidemiological context. Circulation 72, 451 (1985).
  Google Scholar
• NIH Consensus Development Conference. Lowering blood cholesterol to prevent heart disease. NIH Consensus Development Conference Statement. Nutr. Rev. 43, 283–291 (1985).
• Kirby, T. J. Cataracts produced by triparanol. (MER-29). Trans. Am. Ophthalmol. Soc. 65, 494–543 (1967).
  CAS PubMed PubMed Central Google Scholar
• Endo, A., Kuroda, M. & Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (Tokyo) 29, 1346–1348 (1976).
  CAS Google Scholar
• Endo, A., Tsujita, Y., Kuroda, M. & Tanzawa, K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. J. Biochem. 77, 31–36 (1977).
  CAS PubMed Google Scholar
• Watanabe, Y. et al. Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia. Atherosclerosis 38, 27–31 (1981).
  CAS PubMed Google Scholar
• Kuroda, M., Tsujita, Y., Tanzawa, K. & Endo, A. Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Lipids 14, 585–589 (1979).
  CAS PubMed Google Scholar
• Tsujita, Y., Kuroda, M., Tanzawa, K., Kitano, N. & Endo, A. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis 32, 307–313 (1979).
  CAS PubMed Google Scholar
• Fears, R., Richards, D. H. & Ferres, H. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 35, 439–449 (1980).
  CAS PubMed Google Scholar
• Singer, I. I., Scott, S., Kazazis, D. M. & Huff, J. W. Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes. Proc. Natl Acad. Sci. 85, 5264–5268 (1988).
  CAS PubMed Google Scholar
• Bergstrom, J. D. et al. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Biochim. Biophys. Acta 1389, 213–221 (1998).
  CAS PubMed Google Scholar
• Alberts, A. W. et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl Acad. Sci. 77, 3957–3961 (1980). Alfred Alberts and colleagues described the discovery and properties of lovastatin (originally named mevinolin), the first statin developed for clinical use.
  CAS PubMed Google Scholar
• Mabuchi, H. et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N. Engl. J. Med. 305, 478–482 (1981).
  CAS PubMed Google Scholar
• Mabuchi, H. et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N. Engl. J. Med. 308, 609–613 (1983).
  CAS PubMed Google Scholar
• Tobert, J. A., Hitzenberger, G., Kukovetz, W. R., Holmes, I. B. & Jones, K. H. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis 41, 61–65 (1982).
  CAS PubMed Google Scholar
• Tobert, J. A. et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. J. Clin. Invest. 69, 913–919 (1982).
  CAS PubMed PubMed Central Google Scholar
• Bilheimer, D. W., Grundy, S. M., Brown, M. S. & Goldstein, J. L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl Acad. Sci. 80, 4124–4128 (1983).
  CAS PubMed Google Scholar
• Illingworth, D. R. & Sexton, G. J. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J. Clin. Invest. 74, 1972–1978 (1984).
  CAS PubMed PubMed Central Google Scholar
• Thompson, G. R., Ford, J., Jenkinson, M. & Trayner, I. Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia. Q. J. Med. 60, 803–811 (1986).
  CAS PubMed Google Scholar
• Havel, R. J. et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann. Intern. Med. 107, 609–615 (1987).
  CAS PubMed Google Scholar
• Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. JAMA 256, 2829–2834 (1986). The first multicentre study with lovastatin in patients with hypercholesterolaemia. Using an unusual hybrid parallel/crossover trial design, this Phase IIb study in 100 patients obtained useful information about the dose–response relationship, time to maximal effect and the relative efficacy of once and twice daily dosing.
• Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA 260, 359–366 (1988).
• Lovastatin Study Group IV. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. Am. J. Cardiol. 66, 22b–30b (1990).
• Tang, J. L. et al. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 316, 1213–1220 (1998).
  CAS PubMed PubMed Central Google Scholar
• Bradford, R. H. et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. 151, 43–49 (1991).
  CAS PubMed Google Scholar
• Gerson, R. J. et al. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am. J. Med. 87, 28s–38s (1989).
  CAS PubMed Google Scholar
• Smith, P. F. et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J. Pharmacol. Exp. Ther. 257, 1225–1235 (1991).
  CAS PubMed Google Scholar
• Downs, J. R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615–1622 (1998).
  CAS Google Scholar
• Coronary Drug Project. Clofibrate and niacin in coronary heart disease. JAMA 231, 360–381 (1975).
• Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251, 351–364 (1984).
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994). This landmark study provided unequivocal evidence that lowering cholesterol with a statin reduced all-cause mortality. It essentially ended the cholesterol controversy.
• Pedersen, T. R. et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. 156, 2085–2092 (1996). This paper provides an exploration of the safety of simvastatin in 4S, in more detail than was possible in the original paper.
  CAS PubMed Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22 (2002). One of the largest long-term clinical trials ever done, the Heart Protection Study demonstrated the benefit and safety of simvastatin in a broad array of patient types with coronary heart disease (CHD) or those at high risk of CHD due to diabetes or non-coronary atherosclerotic vascular disease, including those with low-density lipoprotein cholesterol well below the United Kingdom population average.
• Shepherd, J. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301–1307 (1995).
  CAS PubMed Google Scholar
• Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001–1009 (1996).
  CAS PubMed Google Scholar
• The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339, 1349–1357 (1998).
• Serruys, P. W. J. C. et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 287, 3215–3222 (2002).
  CAS PubMed Google Scholar
• Sever, P. S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149–1158 (2003).
  CAS Google Scholar
• Chylack, L. T. Jr, Mantell, G., Wolfe, J. K., Friend, J. & Rosner, B. Lovastatin and the human lens; results of a two year study. The MSDRL Study Group. Optom. Vis. Sci. 70, 937–943 (1993).
  PubMed Google Scholar
• Schmidt, J., Schmitt, C. & Hockwin, O. No lens changes caused by simvastatin results from a prospective drug safety study. Lens Eye Toxic. Res. 7, 643–650 (1990).
  CAS PubMed Google Scholar
• Harris, M. L. et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br. J. Ophthalmol. 79, 996–1002 (1995).
  CAS PubMed PubMed Central Google Scholar
• Schmidt, J., Schmitt, C., Hockwin, O., Paulus, U. & von Bergmann, K. Ocular drug safety and HMG-CoA-reductase inhibitors. Ophthalmic Res. 26, 352–360 (1994).
  CAS PubMed Google Scholar
• Laties, A. M. et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin. Am. J. Cardiol. 67, 447–453 (1991).
  CAS PubMed Google Scholar
• Tolman, K. The liver and lovastatin. Am. J. Cardiol. 89, 1374–1380 (2002).
  CAS PubMed Google Scholar
• LaRosa, J., He, J. & Vupputuri, S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282, 2340–2346 (1999).
  CAS PubMed Google Scholar
• Pedersen, T. R. et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am. J. Cardiol. 86, 257–262 (2000).
  CAS PubMed Google Scholar
• Eckernas, S. A. et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br. J. Clin. Pharmacol. 35, 284–289 (1993).
  CAS PubMed PubMed Central Google Scholar
• Kostis, J. B., Rosen, R. C. & Wilson, A. C. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J. Clin. Pharmacol. 34, 989–996 (1994).
  CAS PubMed Google Scholar
• Partinen, M. et al. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. Am. J. Cardiol. 73, 876–880 (1994).
  CAS PubMed Google Scholar
• Harrison, R. W. & Ashton, C. H. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br. J Clin. Pharmacol. 37, 231–236 (1994).
  CAS PubMed PubMed Central Google Scholar
• Gengo, F. et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin. Cardiol. 18, 209–214 (1995).
  CAS PubMed Google Scholar
• Wardle, J. et al. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group. BMJ 313, 75–78 (1996).
  CAS PubMed PubMed Central Google Scholar
• Norman, D. J., Illingworth, D. R., Munson, J. & Hosenpud, J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N. Engl. J. Med. 318, 46–47 (1988).
  CAS PubMed Google Scholar
• Pierce, L. R., Wysowski, D. K. & Gross, T. P. Myopathy and rhabdomyolysis associated with lovastatin–gemfibrozil combination therapy. JAMA 264, 71–75 (1990).
  CAS PubMed Google Scholar
• Gruer, P., Vega, J., Mercuri, M., Dobrinska, M. & Tobert, J. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. J. Cardiol. 84, 811–815 (1999).
  CAS PubMed Google Scholar
• Ballantyne, C. M. et al. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. 163, 553–564 (2003).
  CAS PubMed Google Scholar
• Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47 (1986). A summary of the work that won the authors the Nobel Prize for Medicine or Physiology in 1985.
  CAS PubMed Google Scholar
• Pappu, A. S. & Illingworth, D. R. Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia. J. Lab. Clin. Med. 114, 554–562 (1989).
  CAS PubMed Google Scholar
• Naoumova, R. P. et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 119, 203–213 (1996).
  CAS PubMed Google Scholar
• Brown, M. S. & Goldstein, J. L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21, 505–517 (1980).
  CAS PubMed Google Scholar
• Balasubramaniam, S., Goldstein, J. L. & Brown, M. S. Regulation of cholesterol synthesis in rat adrenal gland through coordinate control of 3-hydroxy-3-methylglutaryl coenzyme A synthase and reductase activities. Proc. Natl Acad. Sci. 74, 1421–1425 (1977).
  CAS PubMed Google Scholar
• Bergstrom, J. D., Wong, G. A., Edwards, P. A. & Edmond, J. The regulation of acetoacetyl-CoA synthetase activity by modulators of cholesterol synthesis in vivo and the utilization of acetoacetate for cholesterogenesis. J. Biol. Chem. 259, 14548–14553 (1984).
  CAS PubMed Google Scholar
• Kovanen, P. T., Bilheimer, D. W., Goldstein, J. L., Jaramillo, J. J. & Brown, M. S. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc. Natl Acad. Sci. 78, 1194–1198 (1981).
  CAS PubMed Google Scholar
• Ma, P. T. et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc. Natl Acad. Sci. 83, 8370–8374 (1986).
  CAS PubMed Google Scholar
• Reihnér, E. et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323, 224–228 (1990).
  PubMed Google Scholar
• Arad, Y., Ramakrishnan, R. & Ginsberg, H. N. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 41, 487–498 (1992).
  CAS PubMed Google Scholar
• Marais, A. D. et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. 38, 2071–2078 (1997).
  CAS PubMed Google Scholar
• Raal, F. J. et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis 135, 249–256 (1997).
  CAS PubMed Google Scholar
• Steinberg, D. The cholesterol controversy is over. Why did it take so long? Circulation 80, 1070–1078 (1989).
  CAS PubMed Google Scholar
• Muldoon, M. F., Manuck, S. B. & Matthews, K. A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301, 309–314 (1990).
  CAS PubMed PubMed Central Google Scholar
• Davey Smith, G. & Pekkanen, J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 304, 431–434 (1992).
  CAS PubMed PubMed Central Google Scholar
• Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269, 3015–3023 (1993).
• Pyörälä, K. et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J. 15, 1300–1331 (1994).
  PubMed Google Scholar
• Blankenhorn, D. H. et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann. Intern. Med. 119, 969–976 (1993).
  CAS PubMed Google Scholar
• MAAS investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344, 633–638 (1994).
• Waters, D. et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89, 959–968 (1994).
  CAS PubMed Google Scholar
• Jukema, J. W. et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91, 2528–2540 (1995).
  CAS PubMed Google Scholar
• Pitt, B. et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J. Am. Coll. Cardiol. 26, 1133–1139 (1995).
  CAS PubMed Google Scholar
• Furberg, C. D. et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group Circulation 90, 1679–1687 (1994).
  CAS PubMed Google Scholar
• Salonen, R. et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92, 1758–1764 (1995).
  CAS PubMed Google Scholar
• Oliver, M. F. Serum cholesterol — the knave of hearts and the joker. Lancet 2, 1090–1095 (1981).
  CAS PubMed Google Scholar
• Oliver, M. F. Is cholesterol reduction always safe? Eur. J. Clin. Invest. 22, 441–442 (1992).
  CAS PubMed Google Scholar
• Oliver, M., Poole-Wilson, P., Shepherd, J. & Tikkanen, M. Lower patients' cholesterol now. BMJ 310, 1280–1281 (1995).
  CAS PubMed PubMed Central Google Scholar
• Collins, R. & MacMahon, S. Reliable assessment of the effects of treatment on mortality and major morbidity. I: clinical trials. Lancet 357, 373–380 (2001). An excellent guide to the concepts underlying the 'megatrial', such as the large long-term clinical trials that have been crucial to the success of the statins.
  CAS PubMed Google Scholar
• LaRosa, J. C. Pleiotropic effects of statins and their clinical significance. Am. J. Cardiol. 88, 291–293 (2001).
  CAS PubMed Google Scholar
• Vita, J. A. et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102, 846–851 (2000).
  CAS PubMed Google Scholar
• Vollmer, T. et al. An open-label, single arm study of simvastatin as a therapy for multiple sclerosis (MS). 55th Annual Meeting of the American Association of Neurology Abstract S11. 004 (2003).
  Google Scholar
• Raine, J. M. Withdrawal of cerivastatin (Libobay) by Bayer PLC. (Department of Health, Medicines Control Agency, London, 2001).
• Editorial. How a statin might destroy a drug company. Lancet 361, 793 793 (2003).
• Magarian, G. J., Lucas, L. M. & Colley, C. Gemfibrozil-induced myopathy. Arch. Intern. Med. 151, 1873–1874 (1991).
  CAS PubMed Google Scholar
• Backman, J., Kyrklund, C., Neuvonen, M. & Neuvonen, P. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685–691 (2002).
  CAS PubMed Google Scholar
• Stein, E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am. J. Cardiol. 82, 40j–46j (1998).
  CAS PubMed Google Scholar
• Yusuf, S. Two decades of progress in preventing vascular disease. Lancet 360, 2–3 (2002). An editorial on the Heart Protection Study that summarizes the advances made with statins and other drugs for preventing cardiovascular morbidity and mortality.
  PubMed Google Scholar
• MacMahon, M. et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis. 10, 195–203 (2000).
  CAS PubMed Google Scholar
• Davidson, M. H. Statin trials in progress: unanswered questions. Curr. Atheroscler. Rep. 3, 9–13 (2001).
  CAS PubMed Google Scholar
• Bruckert, E. New lipid-modifying therapies. Expert Opin. Investig. Drugs 12, 325–335 (2003).
  CAS PubMed Google Scholar